Showing 2762 results
- Key Release /Ad hoc announcement pursuant to Art. 53 LRPhase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal nocturnal hemoglobinuria (PNH) patients…
- Media Release /Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and…
- Media Release /Transformation to pure-play Innovative Medicines company nears completion Focusing strategy on five core Therapeutic Areas, key technology platforms, and the US Advancing eight in-…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Basel, 21 September, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied its…
- Media Release /ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in…
- Media Release /Company confident to clarify legitimacy of its position and fully cooperating with authorities Basel, September 15, 2022 — Novartis today confirms that it has been contacted by the Swiss…
- Media Release /Multi-year investment of USD 300m will create integrated scientific environment to deliver on increasing growth and diversity of biotherapeutics portfolio Enhanced capacity and processes…
- Media Release /RATIONALE 301 trial met its objective at final analysis, demonstrating non-inferior overall survival (OS) for tislelizumab (median OS: 15.9 months) versus sorafenib (median OS: 14.1 months) in…
- Media Release /Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and…
- Key Release /Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven by key growth brands including: Entresto (+31% cc),…
Pagination
- ‹ Previous page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- …
- 277
- › Next page